PYXS - Pyxis Oncology, Inc.

QQQ $ 623.93 $ 0.68 (0.11 %)

DIA $ 471.69 $ 1.32 (0.28 %)

SPY $ 678.12 $ 1.99 (0.29 %)

TLT $ 89.96 $ 0.17 (0.19 %)

GLD $ 365.34 $ 1.73 (0.48 %)

Previous Close

$ 3.81

Open

$ 3.75

Bid

$ 3.95 x 500

Ask

$ 3.97 x 300

Day's Range

$ 3.64 - $ 4.15

52 Week Range

$ 0.83 - $ 5.39

Volume

1,770,269

Average Volume

Market Cap

238.34M

Beta (5Y Monthly)

$ 1.54

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-03-2025	09-30-2025	10-Q
2	08-14-2025	06-30-2025	10-Q
3	05-15-2025	03-31-2025	10-Q
4	03-18-2025	12-31-2024	10-K
5	11-12-2024	09-30-2024	10-Q
6	08-14-2024	06-30-2024	10-Q
7	05-14-2024	03-31-2024	10-Q
8	03-21-2024	12-31-2023	10-K
9	11-07-2023	09-30-2023	10-Q
10	08-11-2023	06-30-2023	10-Q
11	05-11-2023	03-31-2023	10-Q
12	03-22-2023	12-31-2022	10-K
13	11-01-2022	09-30-2022	10-Q
14	08-15-2022	06-30-2022	10-Q
15	05-13-2022	03-31-2022	10-Q
16	03-29-2022	12-31-2021	10-K
17	11-15-2021	09-30-2021	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Guggenheim Maintains Buy on Pyxis Oncology...
11/04/2025 15:37:04

Guggenheim analyst Brad Canino maintains Pyxis Oncology (NASDAQ:PYXS) with a Buy and raises the price target from $5 to $7.

Pyxis Oncology Q3 EPS $(0.35) Misses $(0.3...
11/03/2025 12:09:28

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0....

Pyxis Oncology To Present Translational Da...
10/13/2025 20:09:59

BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generati...

12 Health Care Stocks Moving In Monday's A...
10/06/2025 21:06:27

Guggenheim Initiates Coverage On Pyxis Onc...
09/04/2025 13:54:29

Guggenheim analyst Brad Canino initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Buy rating and announces Price Targ...

HC Wainwright & Co. Reiterates Buy on Pyxi...
08/19/2025 11:02:47

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $5 p...

Pyxis Oncology Q2 EPS $(0.30) Beats $(0.35...
08/14/2025 20:36:54

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.35...

Pyxis Oncology Updates Enrollment for Phas...
08/04/2025 11:29:11

On July 31, 2025, revisions to patient enrollment participants related to Pyxis Oncology, Inc.'s (the "Company") Ph...

HC Wainwright & Co. Reiterates Buy on Pyxi...
05/19/2025 10:55:33

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $5 p...

Pyxis Oncology Q1 EPS $(0.35) Misses $(0.2...
05/15/2025 11:10:59

Pyxis Oncology Announces Robust Preclinica...
04/25/2025 17:20:38

Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identif...

Pyxis Oncology Will Present New Preclinica...
03/25/2025 20:32:51

Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat can...

Pyxis Oncology To Present Preclinical Data...
03/25/2025 20:31:21

RBC Capital Reiterates Outperform on Pyxis...
03/19/2025 14:44:15

RBC Capital analyst Leonid Timashev reiterates Pyxis Oncology (NASDAQ:PYXS) with a Outperform and maintains $8 price target.

HC Wainwright & Co. Reiterates Buy on Pyxi...
03/19/2025 10:37:50

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $5 p...

As Of December 31, 2024, Pyxis Oncology Ha...
03/18/2025 11:34:29

Pyxis Oncology FY 2024 GAAP EPS $(1.32) Mi...
03/18/2025 11:33:04

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1....

Pyxis Oncology Granted FDA Fast Track Desi...
02/26/2025 12:31:26

Pyxis Oncology Initiates Phase 1/2 Combina...
02/04/2025 12:36:56

pyxis-oncologys-deprioritizes-second-pipeline-asset-analyst-applauds-move

Pyxis Oncology's Deprioritizes Second Pipe...
12/20/2024 16:13:53

Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritizing PYX-106 due to resource...